Document:

onvo-ex41_10.htm

Exhibit 4.1

DESCRIPTION OF ORGANOVO HOLDINGS, INC.’S SECURITIES 

REGISTERED PURSUANT TO SECTION 12 OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

The following description of the common stock, par value $0.001 per share, of Organovo Holdings, Inc. (“us,” “our,” “we,” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),  summarizes certain information regarding the common stock in our certificate of incorporation, as amended, our by-laws, as amended, and applicable provisions of Delaware general corporate law (the “DGCL”), and is qualified by reference to our certificate of incorporation, our certificate of amendment of certificate of incorporation, our by-laws and our amendment to bylaws, which are incorporated by reference as Exhibit 3.1, 3.2, 3.3, 3.4 and 3.5, respectively, to the Annual Report on Form 10-K for the fiscal year ending March 31, 2021.

Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share and 25,000,000 shares of preferred stock, par value $0.001 per share.

General

As of March 31, 2021, our certificate of incorporation, as amended (the “certificate of amendment”), authorizes us to issue up to (i) 200,000,000 shares of common stock, par value $0.001 per share, and (ii) 25,000,000 shares of preferred stock, par value $0.001 per share. 

 

On August 18, 2020, we effected a 1-for-20 reverse stock split of our outstanding common stock. As a result of the reverse stock split, every twenty (20) shares of our pre-reverse split common stock were combined and reclassified into one (1) share of common stock. The reverse stock split had no effect on the number of authorized shares of common or preferred stock, or on the stated par value per share of our common stock.

The following is a summary of the material provisions of the common stock and preferred stock provided for in our Certificate of Incorporation and bylaws, as amended (the “bylaws”). For additional detail about our capital stock, please refer to our Certificate of Incorporation and bylaws.

Common Stock

Our common stock is listed on the Nasdaq Capital Market under the symbol “ONVO”.

Voting: Holders of our common stock are entitled to one vote for each share on all matters submitted to a stockholder vote, except matters that relate only to a series of our preferred stock.

The holders of common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors. Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all shares of common stock that are present in person or represented by proxy. Except as otherwise provided by law, amendments to the certificate of incorporation generally must be approved by a majority of the votes entitled to be cast by all outstanding shares of common stock. The certificate of incorporation does not provide for cumulative voting in the election of directors. The common stock holders will be entitled to such cash dividends as may be declared from time to time by our board of directors from funds available. Upon our liquidation, dissolution or winding up, the common stock holders will be entitled to receive pro rata all assets available for distribution to such holders.

 

Dividends: Subject to limitations under Delaware law and preferences that may apply to any then-outstanding shares of preferred stock, holders of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by our board of directors in its discretion from funds legally available therefor.

 

 

Dividends, if any, will be contingent upon our revenues and earnings, if any, and capital requirements and financial conditions. The payment of dividends, if any, will be within the discretion of our board of directors. We presently intend to retain all earnings, if any, and accordingly our board of directors does not anticipate declaring any dividends prior to a business combination.

Liquidation: In the event of a liquidation, dissolution or winding up, the holders of common stock are entitled to share pro rata all assets remaining after payment in full of all liabilities and after providing for each class of stock, if any, having preference over the common stock, subject to the liquidation preference of any then outstanding shares of preferred stock.

Miscellaneous: Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

Preferred Stock

Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. There are no restrictions presently on the repurchase or redemption of any shares of our preferred stock.

The issuance of preferred stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. The effects of issuing preferred stock could include one or more of the following:

 

	
 
	
•
	
restricting dividends on the common stock;

 

	
 
	
•
	
diluting the voting power of the common stock;

 

	
 
	
•
	
impairing the liquidation rights of the common stock; or

 

	
 
	
•
	
delaying or preventing changes in control or management of our company.

We have no present plans to issue any shares of preferred stock nor are any shares of our preferred stock presently outstanding. 

Effect of Certain Provisions of our Certificate of Incorporation and Bylaws

Provisions of our certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, may have the effect of discouraging takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.

 

 

 

Classified Board. Our Certificate of Incorporation and our Bylaws provide that our board of directors is divided into three classes, consisting of one Class I director, two Class II directors and two Class III directors. The directors designated as Class I directors have a term expiring at our annual meeting of stockholders in 2021. The directors designated as Class II directors have a term expiring at our annual meeting of stockholders in 2022, and the directors designated as a Class III directors have a term expiring at our annual meeting of stockholders in 2023. Directors for each class will be elected at the annual meeting of stockholders held in the year in which the term for that class expires and thereafter will serve for a term of three years. At any meeting of stockholders for the election of directors at which a quorum is present, the election will be determined by a plurality of the votes cast by the stockholders entitled to vote at the election. Under the classified board provisions, it will take at least two elections of directors for any individual or group to gain control of our board. Accordingly, these provisions could discourage a third party from initiating a proxy contest, making a tender offer or otherwise attempting to gain control of us.

Undesignated preferred stock. The authority of our board of directors to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control of our company through a merger, tender offer, proxy contest, or otherwise by making it more difficult or more costly to obtain control of our company. Our board of directors may issue preferred stock with voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of common stock.

Advanced Notice Requirement. Stockholder nominations of individuals for election to our board of directors and stockholder proposals of other matters to be brought before an annual meeting of our stockholders must comply with the advance notice procedures set forth in our bylaws. Generally, to be timely, such notice must be received at our principal executive offices no later than the date specified in our proxy statement released to stockholders in connection with the preceding year’s annual meeting of stockholders, which date shall be not earlier than the 75th day, nor later than the close of business on the 45th day, prior to the one-year anniversary of the date on which we first mailed our proxy materials or a notice of availability of proxy materials (whichever is earlier) for the preceding year’s annual meeting.

Special Meeting Requirements. Our bylaws provide that special meetings of our stockholders may only be called at the request of a majority of the authorized number of members of the board of directors, chairperson of the board of directors, chief executive officer, president or secretary. Only such business shall be considered at a special meeting as shall have been stated in the notice for such meeting.

No Stockholder Action by Written Consent Except with Prior Board Approval: Our Certificate of Incorporation and Bylaws provide that no action shall be taken by our stockholders except at an annual or special meeting of the stockholders called in accordance with the Bylaws, and no action shall be taken by our stockholders by written consent, except if the action to be effected by written consent and the taking of such action by written action is approved in advance by resolution of the board of directors.

No Cumulative Voting. Our certificate of incorporation does not include a provision for cumulative voting for directors.

Removal of Directors. Our certificate of incorporation and bylaws provide that the holders of our voting stock may only remove our directors for cause.

Authorized but Unissued Shares. Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

 

 

Size of Board and Vacancies. Our bylaws provide that the number of directors on our board of directors is fixed exclusively by our board of directors. Vacancies and newly created directorships resulting from any increase in our authorized number of directors will be filled by a majority of our board of directors then in office, although less than a quorum, or by a sole remaining director.

Indemnification. Our certificate of incorporation and our bylaws provide that we will indemnify our officers and directors against losses as they incur in investigations and legal proceedings resulting from their services to us, which may include service in connection with takeover defense measures.

Delaware Anti-Takeover Statute

We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. In general, Section 203 generally prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless:

 

	
 
	
•
	
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

	
 
	
•
	
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or 

 

	
 
	
•
	
at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder.

In general, Section 203 defines business combination to include the following:

 

	
 
	
•
	
any merger or consolidation involving the corporation and the interested stockholder;

 

	
 
	
•
	
any sale, lease, exchange, mortgage, transfer, pledge or other disposition of 10% or more of either the assets or outstanding stock of the corporation involving the interested stockholder;

 

	
 
	
•
	
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

	
 
	
•
	
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

 

	
 
	
•
	
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines interested stockholder as an entity or person who, together with affiliates and associates, beneficially owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

The provisions of Delaware law and our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions may make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.Exhibit 10.1

 

INVO
BIOSCIENCE, INC.

 

AMENDED
AND RESTATED EMPLOYMENT AGREEMENT

 

for

 

Andrea
Goren

 

This
Employment Agreement (the “Agreement”) is entered into as of June 14, 2021 (the “Effective Date”), by and between
INVO Bioscience, Inc., a Nevada corporation (the “Company”), and Andrea Goren (the “Executive”). Capitalized
terms not defined in the body of this Agreement, are defined in Exhibit A attached hereto.

 

WHEREAS,
the Executive has agreed to be employed by the Company as chief financial officer,

 

WHEREAS,
the Company desires that the Executive be retained to serve in the capacity of chief financial officer of the Company;

 

Executive’s
Duties and Obligations.

 

A.
Duties. The Executive shall serve as the Company’s chief financial officer. The Executive shall be responsible for all powers
and duties reasonably associated with that office or position in a publicly-traded company. The Executive shall report directly to the
Company’s CEO and Board and shall be subject to reasonable policies established by the Board.

 

B.
Location of Employment. While the Company’s headquarters are located in Sarasota, Florida, it is understood that the Executive
may work remotely from his home office. In addition, the Executive acknowledges and agrees that the performance by the Executive of the
Executive’s duties may require travel including, without limitation, overseas travel from time to time.

 

C.
Proprietary Information and Invention Agreement. In consideration of the covenants contained herein, the Executive has executed
and agrees to be bound by the Proprietary Information and Invention Agreement (the “Confidentiality Agreement”) attached
to this Agreement as Exhibit B and incorporated into this Agreement by reference. The Executive shall comply at all times with the covenants
(including covenants not to solicit employees and independent contractors) and other terms and conditions of the Confidentiality Agreement
and all other reasonable policies of the Company governing the confidential nature and assignment of the Company’s proprietary
information. The Executive’s obligations under the Confidentiality Agreement shall survive the Term of Employment.

 

2. Devotion
of Time to the Company’s Business.

 

A.
Full-Time Efforts. During the Term of Employment, the Executive shall devote substantially all of his business time, attention
and effort to the affairs of the Company, excluding any periods of disability, vacation, or sick leave to which Executive is entitled,
and shall use his reasonable best efforts to perform the duties properly assigned to him hereunder and to promote the interests of the
Company.

 

    	- 1 -

     

    

 

B.
Other Activities. Executive may pursue outside activities, including serving on corporate, civic or charitable boards or committees,
deliver lectures and fulfilling speaking engagements and may manage personal investments that do not give rise to a conflict of interest
through the Executive’s investment in direct competitors of the Company; provided that such activities do not individually or in
the aggregate significantly interfere with the performance of his duties under this Agreement. In addition, Executive is allowed to continue
his participation in outside professional associations (and the Company will pay all reasonable membership dues for such professional
associations). The Executive’s passive investment in securities of a publicly-held company will not be considered to give rise
to a conflict of interest if the Executive owns not more than 5% of the outstanding securities of such publicly-held company.

 

3. Compensation
and Benefits.

 

A.
Base Salary. The Company shall pay to the Executive in accordance with its normal payroll practices an annual salary at a rate
of $215,000 per annum (“Base Salary”). The Executive’s Base Salary shall be reviewed at least annually or more frequently
as needed for the purposes of determining any changes in role, time efforts, increases based on the Executive’s performance, the
performance of the Company, the then prevailing salary scales for comparable positions, inflation and other relevant factors. Effective
as of the date of any increase in the Executive’s Base Salary, Base Salary as so increased shall be considered the new Base Salary
for all purposes of this Agreement and may not thereafter be reduced.

 

B.
Cash Bonuses. The Company may pay the Executive an annual cash bonus (“Annual Bonus”) in accordance with the terms
hereof and the terms of any annual cash bonus incentive plan maintained for the Company’s key executive officers, as amended from
time to time (the “Key Executive Incentive Plan”) during the Term of Employment. Not later than ninety (90) days after the
beginning of each Fiscal Year, the Compensation Committee, in consultation with the Company’s Chief Executive Officer, shall establish
threshold, target and maximum performance goals for such Fiscal Year in accordance with the terms of Key Executive Incentive Plan. If
the threshold performance goals for a Fiscal Year are attained, the Annual Bonus for such Fiscal Year shall be up to 50% of the base
salary. At the conclusion of the Fiscal Year the Compensation Committee will review performance relative to the performance goals and
if the Compensation Committee determines that the Executive has earned an Annual Bonus, the Company will pay the Annual Bonus to the
Executive within five (5) business days after the Company’s annual earnings report is released but in no event later than the 15th
day of the third calendar month following the end of such Fiscal Year.

 

    	- 2 -

     

    

 

C.
Equity Awards.

 

	 	(i)	Equity
    Award. Subject to the approval of the Board, Employee will receive an award of (i) 5,000 restricted shares of the Company’s
    common stock and (ii) 72,500 options to purchase common stock at an exercise price valued at 100% of the fair market value (calculated
    in accordance with the Company’s 2019 Stock Incentive Plan) on the date of this Agreement. Such grant of restricted shares
    and options will be made substantially concurrently with the execution of this Agreement; provided however that no options shall
    vest or be exercisable until sufficient shares become available under the Company’s 2019 Stock Incentive Plan on January 1,
    2022 in accordance with the annual increase provisions contained in Section 4.2 thereunder Such restricted shares and options shall
    be subject to such terms and conditions, including vesting conditions, as set forth in a separate award agreement between the Company
    and the Employee. All unvested restricted shares and options shall be forfeited upon the Executive’s Date of Termination. Except
    as provided in Section 5 of this Agreement, all unvested restricted shares and options shall be forfeited upon the Executive’s
    Date of Termination.
	 	 	 
	 	(ii)	Annual
    Equity Awards. Executive is eligible to receive Equity Awards each year in the discretion of the Compensation Committee. The
    number of shares of the common stock subject to such annual grant of Equity Awards shall be based on Executive’s performance
    across a wide set of criteria.
	 	 	 
	 	(iii)	Acceleration.
    The Board will take all appropriate steps to ensure that all Equity Awards granted to Executive, to the extent not already vested
    in accordance with their terms, will be fully vested immediately prior to a Change of Control Date.

 

D.
Benefits. During the Term of Employment, the Executive shall be entitled to participate in all employee benefit plans, programs
and arrangements made available generally to the Company’s other full-time employees on substantially the same basis that such
benefits are provided to other full-time employees (including, without limitation profit-sharing, savings and other retirement plans
or programs (e.g., a 401(k) plan), long-term cash incentive plan, program or arrangement, medical, dental, hospitalization, vision, short-
term and long-term disability and life insurance plans or programs, accidental death and dismemberment protection, travel accident insurance,
and any other fringe benefit or employee welfare benefit plans or programs that may be sponsored by the Company from time to time, including
any plans or programs that supplement the above-listed types of plans or programs, whether funded or unfunded); provided, however, that
during the Term of Employment, the Executive shall not be eligible to participate in any generally available severance benefit plan,
program or arrangement sponsored or maintained by the Company. Nothing in this Section 3(d) of the Agreement shall be construed to require
the Company to establish or maintain any such fringe or employee benefit plans, programs or arrangements.

 

E.
PTO. During the Term of Employment, the Executive shall be entitled to twenty-five (25) days paid time off per year.

 

F.
Reimbursement of Expenses. During the Term of Employment, the Executive shall be entitled to receive prompt reimbursement for
all reasonable business- or employment-related expenses incurred by the Executive upon the receipt by the Company of reasonable documentation
in accordance with standard practices, policies and procedures applicable to other senior executives of the Company.

 

    	- 3 -

     

    

 

4.
Termination of Employment. The
Term of Employment shall commence on the date of this Agreement and shall be automatically terminated upon the first to occur of the
following:

 

A.
Death. The Executive’s employment shall terminate immediately upon the Executive’s death.

 

B.
Disability. If the Executive is Disabled, either party may terminate the Executive’s employment due to such Disability upon
delivery of written notice to the other party. The effective date of such termination of employment will be the Date of Termination set
forth in such written notice or immediately upon delivery of such written notice if no effective date is specified in the written notice.
For avoidance of doubt, If the Executive’s employment is terminated pursuant to this Section 6(b), his employment will not constitute
a termination of employment by the Company without Cause or by the Executive for Good Reason.

 

C.
Termination by the Executive Without Good Reason. The Executive may terminate his employment for any reason other than Good Reason
upon his delivery of written notice to the Company at least thirty (30) days prior to his Date of Termination.

 

D.
Termination by the Executive for Good Reason. The Executive may terminate his employment for Good Reason if (i) not later than
ninety (90) days after the occurrence of any act or omission that constitutes Good Reason, the Executive provides the Company with a
written notice setting forth in reasonable detail the acts or omissions that constitute Good Reason, (ii) the Company fails to correct
or cure the acts or omissions within thirty (30) days after it receives such written notice, and (iii) Executive terminates his employment
with the Company after the expiration of such cure period but not later than sixty (60) days after the expiration of such cure period.

 

E.
Termination by the Company Without Cause. The Company may terminate the Executive’s employment without Cause upon delivery
of written notice to the Executive at least thirty (30) days prior to his Date of Termination.

 

F.
Termination by the Company for Cause. Upon the occurrence of any act or omission that constitutes Cause, the Company may terminate
the Executive’s employment if:

 

	 	(i)	No
    fewer than 30 days prior to the Date of Termination, the Company provides Executive with written notice (the “Notice of Consideration”)
    of its intent to consider termination of Executive’s employment for Cause, including a reasonably detailed description of the
    acts or omissions that the CEO believes constitute Cause; and
	 	 	 
	 	(ii)	The
    Executive fails to cure the acts or omissions that constitute Cause within 30 days after receiving such Notice of Consideration.

 

The
Executive’s termination of employment will be deemed to be a termination of employment by the Company without Cause unless the
Company establishes its full compliance with the substantive and procedural requirements of this Section 4(f) prior to the Executive’s
Date of Termination.

 

    	- 4 -

     

    

 

5. Compensation
and Benefits Payable Upon of Termination of Employment.

 

A.
Payment of Accrued But Unpaid Compensation and Benefits. Upon the Executive’s termination of employment for any reason,
the Executive (or his estate following the Executive’s death) shall receive (i) a lump sum payment on the Date of Termination in
an amount equal to the sum of the Executive’s earned but unpaid Base Salary through his Date of Termination plus his accrued but
unused vacation days at the Executive’s Base Salary in effect as of his Date of Termination; plus (ii) any other benefits or rights
the Executive has accrued or earned through her Date of Termination in accordance with the terms of the applicable fringe or employee
benefit plans and programs of the Company. Except as provided in Section 5(b) or (c) below or as expressly provided pursuant to the terms
of any employee benefit plan, the Executive will not be entitled to earn or accrue any additional compensation or benefits for any period
following his Date of Termination.

 

B.
Termination of Employment Due to Death or Disability. In addition to the compensation and benefits payable under Section 5(a)
above, if the Executive’s employment is terminated due to his death or Disability, the Executive (or his estate following the Executive’s
death) shall receive:

 

	 	(i)	the
    Executive’s accrued but unpaid Annual Bonus, if any, for the Fiscal Year ended prior to his Termination Date payable at the
    same time such annual bonuses for such Fiscal Year are paid to other key executives of the Company pursuant to the terms of the Key
    Executive Incentive Plan;
	 	 	 
	 	(ii)	100%
    of the Executive’s outstanding Equity Awards as of the Date of Termination will be fully vested and exercisable.

 

C.
Termination of Employment by the Company without Cause or by the Executive for Good Reason. In addition to the compensation and
benefits payable under Section 5(a) above, if the Executive’s employment is terminated (i) by the Company without Cause or (ii)
by the Executive for Good Reason, and the Executive returns an executed Release (as defined in Section 6 below) to the Company, which
becomes final, binding and irrevocable within sixty (60) days following the Executive’s Date of Termination in accordance with
Section 6, the Executive (or his estate following the Executive’s death) shall receive (provided that Executive shall not be entitled
to receive any of the following if such employment is terminated within 60 days of the Effective Date):

 

		(i)	the
                                            Executive’s accrued but unpaid Annual Bonus, if any, for the Fiscal Year ended prior
                                            to his Termination Date payable at the same time annual bonuses for such Fiscal Year are
                                            paid to other key executives of the Company pursuant to the terms of the Key Executive Incentive
                                            Plan;

 

		(ii)	the
                                            Executive will receive the Annual Bonus, if any, payable for the Fiscal Year in which the
                                            Executive’s employment is terminated based on actual Fiscal Year performance (pro-rated
                                            for the period of employment during such Fiscal Year through the Date of Termination) payable
                                            at the same time annual bonuses for such Fiscal Year are paid to other key executives of
                                            the Company pursuant to the terms of the Key Executive Incentive Plan;

 

    	- 5 -

     

    

 

	 	(iii)	the
    Executive will receive a distribution or payment in settlement of each outstanding long-term performance-based Equity Award (including
    performance shares or other long-term Equity Awards that vest based on measures of long-term performance but excluding the Annual
    Bonus) for the applicable performance period in which Executive’s employment is terminated (pro-rated for the portion of the
    performance period through the Date of Termination) and based on actual performance, payable when such long-term incentive compensation
    would have been payable had Executive’s employment continued through the settlement date of such long-term incentive compensation;
	 	 	 
	 	(iv)	100%
    of the Executive’s outstanding Equity Awards (excluding Equity Awards described in Section 5(c)(ii)) will be fully vested and
    exercisable;
	 	 	 
	 	(v)	The
    Executive will receive continued payment of the Executive’s Base Salary (without regard to any reduction in Base Salary that
    constitutes Good Reason) in accordance with the Company’s payroll practices for three (3) months of Base Salary; and
	 	 	 
	 	(vi)	reimbursement
    of the COBRA premiums, if any, paid by the Executive for continuation coverage for the Executive, his spouse and dependents under
    the Company’s group health, dental and vision plans for the lesser of twelve (12) months or the maximum COBRA continuation
    period.

 

Notwithstanding
the foregoing, no payment that is otherwise required to be paid to the Executive pursuant to this Section 5(c) before the Release becomes
final, binding and irrevocable, shall be paid to the Executive until his Release becomes final, binding and irrevocable. In addition,
if the Executive materially breaches this Agreement or the Executive’s Confidential Agreement, then the Company’s continuing
obligations under this Section 5(c) shall cease as of the date of the breach and the Executive shall be entitled to no further payments
hereunder.

 

6. Release.
As a condition of receiving the compensation and benefits described in Section 5(c), Executive must execute a general waiver and
release of any and all claims arising out of Executive’s employment with the Company or Executive’s separation from such
employment (including, without limitation, claims relating to age, disability, sex or race discrimination to the extent permitted by
law), excepting (i) claims based on breach of the Company’s obligations to pay the compensation and benefits described in
Sections 5 or 7 of this Agreement, (ii) claims arising under the Age Discrimination in Employment Act after the date Executive signs
such release, and (iii) any right to indemnification by the Company or to coverage under directors and officers liability insurance
to which Executive is otherwise entitled in accordance with this Agreement and the Company’s articles of incorporation or by
laws or other agreement between Executive and the Company (the “Release”). Such Release shall be in a form tendered to
the Executive by the Company within five (5) business days following the termination of the Executive’s employment by the
Company without Cause or by the Executive for Good Reason, which shall comply with any applicable legislation or judicial
requirements, including, but not limited to, the Older Workers Benefit Protection Act. The compensation and benefits described in
Section 5(c) will not be paid to the Executive if the Executive fails to execute the Release within the time frame specified in such
Release (but in no event later than, if the Executive revokes the Release within the applicable revocation period set forth in such
Release or if the revocation period expires more than sixty (60) days following the Executive’s Date of
Termination.

 

    	- 6 -

     

    

 

7. Mitigation
of Damages. The Executive will not be required to mitigate damages or the amount of any payment
or benefit provided for under this Agreement by seeking other employment or otherwise. The amount of any payment or benefit provided
for under this Agreement will not be reduced by any compensation or benefits earned by the Executive as the result of self-employment
or employment by another employer or otherwise.

 

8. Excess
Parachute Excise Tax. Anything in this Agreement to the contrary notwithstanding, in the event
it shall be determined that any payment, award, benefit or distribution (including any acceleration) by the Company or any entity which
effectuates a transaction described in Section 280G(b)(2)(A)(i) of the Code to or for the benefit of the Executive (whether pursuant
to the terms of this Agreement or otherwise, but determined before application of any reductions required pursuant to this Section 8)
(a “Payment”) would be subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties are incurred
with respect to such excise tax by the Executive (such excise tax, together with any such interest and penalties, are hereinafter collectively
referred to as the “Excise Tax”), the Company will automatically reduce such Payments to the extent, but only to the extent,
necessary so that no portion of the remaining Payments will be subject to the Excise Tax, unless the amount of such Payments that the
Executive would retain after payment of the Excise Tax and all applicable Federal, state and local income taxes without such reduction
would exceed the amount of such Payments that the Executive would retain after payment of all applicable Federal, state and local taxes
after applying such reduction. Unless otherwise elected by the Executive, to the extent permitted under Code Section 409A, such reduction
shall first be applied to any severance payments payable to the Executive under this Agreement, then to the accelerated vesting on any
Equity Awards, starting with stock options and stock appreciation rights reversing accelerated vesting of those options and stock appreciation
rights with the smallest spread between fair market value and exercise price first and after reversing the accelerated vesting of all
stock options and stock appreciation rights, thereafter reversing accelerated vesting of restricted stock, restricted stock units and
performance shares, performance units or other similar Equity Awards on a pro rata basis.

 

All
determinations required to be made under this Section 8, including the assumptions to be utilized in arriving at such determination,
shall be made by the Company’s independent auditors or such other certified public accounting firm of national standing reasonably
acceptable to the Executive as may be designated by the Company (the “Accounting Firm”) which shall provide detailed supporting
calculations both to the Company and the Executive within 15 business days of the receipt of notice from the Executive that there has
been a Payment, or such earlier time as is requested by either the Company or the Executive. All fees and expenses of the Accounting
Firm shall be borne solely by the Company. If the Accounting Firm determines that no Excise Tax is payable by the Executive, it shall
furnish the Executive with a written opinion to such effect. Any determination by the Accounting Firm shall be binding upon the Company
and the Executive.

 

    	- 7 -

     

    

 

9. Legal
Fees. All reasonable legal fees and related expenses (including costs of experts, evidence and
counsel) paid or incurred by the Executive pursuant to any claim, dispute or question of interpretation relating to this Agreement shall
be paid or reimbursed by the Company if the Executive is successful on the merits pursuant to a legal judgment or arbitration. Except
as provided in this Section 9, each party shall be responsible for its own legal fees and expenses in connection with any claim or dispute
relating to this Agreement.

 

10. Liability
Insurance and Indemnification. The Company shall maintain directors’ and officers’
liability insurance for the Executive during the Term of Employment, and for a six (6) year period following the Executive’s Date
of Termination at a level equivalent to the most favorable and protective coverage for any active officer or director of the Company.
The Company agrees to indemnify the Executive for any job-related liability to the fullest extent permitted under applicable law, and
its by-laws.

 

11.
Notices. All notices, requests, demands and other communications hereunder shall be in
writing and shall be deemed to have been duly given if delivered by hand, email or mailed within the continental United States by first
class certified mail, return receipt requested, postage prepaid, addressed as follows:

 

If
to the Board or the Company:

 

INVO
Bioscience, Inc.

Attention:
CEO

5582
Broadcast Court, Sarasota, Florida 34240

 

If
to the Executive:

 

Andrea
Goren

845
West End Avenue, Apt. 14A

New
York, NY 10025

andrea@goren.io

 

Or
to the address on file with the records of the Company, if more recent.

 

Addresses
may be changed by written notice sent to the other party at the last recorded address of that party.

 

12. Withholding.
The Company shall be entitled to withhold from payments due hereunder any required federal, state or local withholding or other
taxes.

 

13. Arbitration.

 

A.
If the parties are unable to resolve any dispute or claim relating directly or indirectly to this Agreement, the Confidentiality Agreement,
or any dispute or claim between the Executive and the Company and any of its subsidiaries or any of their respective officers, directors,
agents, or employees (a “Dispute”), then either party may require the matter to be settled by final and binding arbitration
by sending written notice of such election to the other party clearly marked “Arbitration Demand.” Thereupon such Dispute
shall be arbitrated in accordance with the terms and conditions of this Section 13. Notwithstanding the foregoing, either party may apply
to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction, or other equitable relief to preserve
the status quo or prevent irreparable harm or to enforce the terms of the Confidentiality Agreement.

 

    	- 8 -

     

    

 

B.
The Dispute shall be resolved by a single arbitrator in an arbitration administered by the Judicial Arbitration & Mediation Services,
Inc. (“JAMS”), pursuant to its Employment Arbitration Rules and Procedures (the “JAMS Rules”) judgment upon the
award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The decision of the arbitrator shall be final
and binding on the parties, and specific performance giving effect to the decision of the arbitrator may be ordered by any court of competent
jurisdiction.

 

C.
Nothing contained herein shall operate to prevent either party from asserting counterclaim(s) in any arbitration commenced in accordance
with this Agreement, and any such party need not comply with the procedural provisions of this Section 13 in order to assert such counterclaim(s).

 

D.
The arbitration shall be filed with the office of the JAMS located in New York, New York or such other JAMS office as the parties may
agree upon (without any obligation to so agree). The arbitration shall be conducted pursuant to the JAMS Rules as in effect at the time
of the arbitration hearing. In addition, the following rules and procedures shall apply to the arbitration:

 

	 	(i)	The
    arbitrator shall have the sole authority to decide whether or not any Dispute between the parties is arbitrable and whether the party
    presenting the issues to be arbitrated has satisfied the conditions precedent to such party’s right to commence arbitration
    as required by this Section 13.
	 	 	 
	 	(ii)	The
    decision of the arbitrator, which shall be in writing and state the findings, the facts and conclusions of law upon which the decision
    is based, shall be final and binding upon the parties, who shall forthwith comply after receipt thereof. Judgment upon the award
    rendered by the arbitrator may be entered by any competent court. Each party submits itself to the jurisdiction of any such court,
    but only for the entry and enforcement to judgment with respect to the decision of the arbitrator hereunder.
	 	 	 
	 	(iii)	The
    arbitrator shall have the power to grant all legal and equitable remedies (including, without limitation, specific performance) and
    award compensatory and punitive damages if authorized by applicable law.
	 	 	 
	 	(iv)	Except
    as otherwise provided in Section 9 or by law, the parties shall bear their own costs in preparing for and participating in the resolution
    of any Dispute pursuant to this Section 13, and the costs of the arbitrator(s) shall be equally divided between the parties.
	 	 	 
	 	(v)	Except
    as provided in the last sentence of Section 13(a), the provisions of this Section 13 shall be a complete defense to any suit, action
    or proceeding instituted in any federal, state or local court or before any administrative tribunal with respect to any Dispute arising
    in connection with this Agreement. Any party commencing a lawsuit in violation of this Section 13 shall pay the costs of the other
    party, including, without limitation, reasonable attorney’s fees and defense costs.

 

    	- 9 -

     

    

 

14. Recoupment.

 

A.
Policy. Any incentive-based compensation received by the Executive including Annual Bonus and Equity Awards, whether pursuant
to this Agreement or otherwise, that is granted, earned or vested based in any part on attainment of a future financial reporting
measure, shall be subject to the terms and conditions of the Company’s Claw Back Compensation Policy, if any (the
“Recoupment Policy”), and any other policy of recoupment of compensation as shall be adopted from time to time by the Board
or its Compensation Committee as it deems necessary or appropriate to comply with the requirements of Section 954 of the Dodd-Frank Wall
Street Reform and Consumer Protection Act, Section 304 of the Sarbanes-Oxley Act of 2002, and any implementing rules and regulations
of the U.S. Securities and Exchange Commission and applicable listing standards of a national securities exchange adopted in accordance
with any of the foregoing. The terms and conditions of the Recoupment Policy, including any changes to the Recoupment Policy adopted
from time to time by the Company, are hereby incorporated by reference into this Agreement.

 

B.
Non-Indemnification and Advancement for Recoupment. The Company shall not be obligated to indemnify or advance funds to the Executive
for any payment or reimbursement by the Executive to the Company of any bonus or other incentive-based or equity-based compensation previously
received by the Executive or payment of any profits realized by the Executive from the sale of securities of the Company, as required
in each case under the Securities Exchange Act of 1934 or under the rules of the stock exchange on which the common stock of the Company
is listed (including any such payments or reimbursements under Section 304 and 306 of the Sarbanes-Oxley Act of 2002, or pursuant to
Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any implementing rules and regulations of the U.S. Securities
and Exchange Commission and applicable listing standards of a national securities exchange adopted in accordance with any of the foregoing).

 

15. Miscellaneous.

 

A.
Governing Law. This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of Florida
without regard to the application of choice of law rules.

 

B.
Entire Agreement. This Agreement, together with the Exhibits attached hereto, contains the entire agreement between the parties
with respect to the subject matter hereof and supersedes any and all other prior agreements, promises, understandings and representations
regarding the Executive’s employment, compensation, severance or other payments contingent upon the Executive’s termination
of employment, whether written or otherwise.

 

C.
Amendments. No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed
by the parties hereto.

 

    	- 10 -

     

    

 

D.
Severability. If one or more provisions of this Agreement are held to be invalid or unenforceable under applicable law, such provisions
shall be construed, if possible, so as to be enforceable under applicable law, or such provisions shall be excluded from this Agreement
and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with
its terms.

 

E.
Binding Effect. This Agreement shall be binding upon and inure to the benefit of the beneficiaries, heirs and representatives
of the Executive and the successors and assigns of the Company. The Company shall require any successor (whether direct or indirect,
by purchase, merger, reorganization, consolidation, acquisition of property or stock, liquidation, or otherwise) to all or substantially
all of its assets, by agreement in form and substance satisfactory to the Executive, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform this Agreement if no such succession had taken
place. Regardless whether such agreement is executed, this Agreement shall be binding upon any successor of the Company in accordance
with the operation of law and such successor shall be deemed the Company for purposes of this Agreement.

 

F.
Successors and Assigns; Nonalienation of Benefits. Except as provided in Section 15(e) in the case of the Company, or to the Executive’s
estate and heirs in the case of the death of the Executive, this Agreement is not assignable by any party. Compensation and benefits
payable to the Executive under this Agreement shall not be subject in any manner to anticipation, alienation, sale, transfer, assignment,
pledge, encumbrance, charge, garnishment, execution or levy of any kind, either voluntary or involuntary, prior to actually being received
by the Executive or his estate, as applicable, and any such attempt to dispose of any right to benefits payable hereunder shall be void,
and no payment to be made hereunder shall be subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or
other charge.

 

G.
Remedies Cumulative; No Waiver. No remedy conferred upon either party by this Agreement is intended to be exclusive of any other
remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given hereunder or now or hereafter
existing at law or in equity. No delay or omission by either party in exercising any right, remedy or power hereunder or existing at
law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time
to time and as often as may be deemed expedient or necessary by such party in such party’s sole discretion.

 

H.
Survivorship. Notwithstanding anything in this Agreement to the contrary, all terms and provisions of this Agreement that by their
nature extend beyond the Date of Termination shall survive termination of this Agreement.

 

I.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all
of which, when taken together, shall constitute one document.

 

16. No
Contract of Employment. Nothing contained in this Agreement will be construed as a right of the Executive to be continued
in the employment of the Company, or as a limitation of the right of the Company to discharge the Executive with or without Cause.

 

    	- 11 -

     

    

 

17.
Section 409A of the Code. The intent of the parties is that payments and benefits under this Agreement comply with, or
be exempt from, Section 409A of the Code and, accordingly, to the maximum extent permitted, this Agreement shall be construed and interpreted
in accordance with such intent. The Executive’s termination of employment (or words to similar effect) shall not be deemed to have
occurred for purposes of this Agreement unless such termination of employment constitutes a “separation from service” within
the meaning of Code Section 409A and the regulations and other guidance promulgated thereunder.

 

Notwithstanding
any provision in this Agreement to the contrary, if the Executive is deemed on the date of the Executive’s separation from service
to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B) and using the identification
methodology selected by the Company from time to time, or if none, the default methodology set forth in Code Section 409A, then with
regard to any payment or any benefit that constitutes “non-qualified deferred compensation” pursuant to Code Section 409A
and the regulations issued thereunder that is payable due to the Executive’s separation from service, to the extent required to
be delayed in compliance with Code Section 409A(a)(2)(B), such payment or benefit shall not be made or provided to the Executive prior
to the earlier of (i) the expiration of the six (6)-month period measured from the date of the Executive’s separation from service,
and (ii) the date of the Executive’s death (the “Delay Period”). On the first day of the seventh month following the
date of the Executive’s separation from service or, if earlier, on the date of the Executive’s death, all payments delayed
pursuant to this Section 17 shall be paid or reimbursed to the Executive in a lump sum, and any remaining payments and benefits due to
the Executive under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.

 

To
the extent any reimbursement of costs and expenses (including reimbursement of COBRA premiums pursuant to Section 5(c)) provided for
under this Agreement constitutes taxable income to the Executive for Federal income tax purposes, such reimbursements shall be made as
soon as practicable after the Executive provides proper documentation supporting reimbursement but in no event later than December 31
of the calendar year next following the calendar year in which the expenses to be reimbursed are incurred. With regard to any provision
herein that provides for reimbursement of expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement
or in-kind benefits is not subject to liquidation or exchange for another benefit, and (ii) the amount of expenses eligible for reimbursement,
or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to
be provided, in any other taxable year.

 

If
under this Agreement, any amount is to be paid in two or more installments, each such installment shall be treated as a separate payment
for purposes of Section 409A.

 

18. Executive
Acknowledgement. The Executive hereby acknowledges that the Executive has read and understands the provisions of this
Agreement, that the Executive has been given the opportunity for the Executive’s legal counsel to review this Agreement, that the
provisions of this Agreement are reasonable and that the Executive has received a copy of this Agreement.

 

[REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

    	- 12 -

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Employment Agreement to be executed on June 14, 2021.

 

	INVO
    BIOSCIENCE, INC.	 
	 	 	 
	By:
    	/s/
    Steve Shum	 
	Name:	Steve
    Shum	 
	Title:
    	CEO	 
	 	 	 
	EXECUTIVE	 
	 	 	 
	/s/
    Andrea Goren	 
	Andrea Goren	 

 

    	- 13 -

     

    

 

EXHIBIT
A

 

	(a)	“Annual
    Bonus” shall have the meaning set forth in Section 5(b) of the Employment Agreement.
	 	 
	(b)	“Base
    Salary” shall have the meaning set forth in Section 5(a) of the Employment Agreement.
	 	 
	(c)	“Board”
    means the Board of Directors of the Company.
	 	 
	(d)	“Cause”
    means one or more of the following:

 

		(i)	The
                                            Executive’s willful and continuous failure to perform his essential duties hereunder
                                            or the lawful directives of the Chief Executive Officer (other than as a result of illness
                                            or injury);

 

	 	(ii)	The
    Executive’s willful misconduct or gross negligence in the performance of his duties hereunder that directly, the could reasonably
    be expected to materially and demonstrably impair or damage the property, goodwill, reputation, business or finances of the Company;
	 	 	 
	 	(iii)	The
    conviction of, or plea of nolo contendere by, the Executive to, a felony or a crime involving moral turpitude that could reasonably
    be expected to materially and demonstrably impair or damage the property, goodwill, reputation, business or finances of the Company;
	 	 	 
	 	(iv)	The
    Executive’s material breach of his obligations under the Confidentiality Agreement;
	 	 	 
	 	(v)	The
    Executive’s willful material violation of the Company policies that could reasonably be expected to materially and demonstrably
    impair or damage the property, goodwill, reputation, business or finances of the Company; or
	 	 	 
	 	(vi)	The
    Executive’s commission of any willful acts of personal dishonesty in connection with his responsibilities as an employee of
    the Company that could reasonably be expected to materially and demonstrably impair or damage the property, goodwill, reputation,
    business or finances of the Company.

 

For
purposes of this definition, no act or failure to act on the part of the Executive shall be considered “willful” unless it
is done, or omitted to be done, by the Executive in bad faith or without a reasonable belief that the action or omission was in the best
interests of the Company. Any act, or failure to act, based on authority given pursuant to a resolution duly adopted by the Board or
any committee thereof, or the advice of counsel to the Company, will be conclusively presumed to be done, or omitted to be done, by the
Executive in good faith and in the best interests of the Company.

 

    	A-1

     

    

 

	(e)	“Change
    of Control” means the occurrence of any one of the following events.

 

	 	(i)	any
    “person” (as defined in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)),
    other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company, an underwriter
    temporarily holding securities pursuant to an offering of such securities or any corporation owned, directly or indirectly, by the
    stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, directly or indirectly
    acquires “beneficial ownership” (as defined in Rule 13d-3 under the Exchange Act) of securities representing more than
    50% of the combined voting power of the Company’s then outstanding securities;
	 	 	 
	 	(ii)	the
    consummation of a reorganization, merger, statutory share exchange, consolidation or similar corporate transaction (each, a “Business
    Combination”) other than a Business Combination in which all or substantially all of the individuals and entities who were
    the beneficial owners of the Company’s voting securities immediately prior to such Business Combination beneficially own, directly
    or indirectly, 50% or more of the combined voting power of the voting securities of the entity resulting from such Business Combination
    (including, without limitation, an entity which as a result of the Business Combination owns the Company or all or substantially
    all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their
    ownership of the Company’s voting securities immediately prior to such Business Combination; or
	 	 	 
	 	(iii)	any
    “person” (as defined in Sections 13(d) and 14(d) of the Exchange Act) acquires all or substantially all of the assets
    of the Company within any twelve (12) consecutive month period.

 

Notwithstanding
the forgoing, none of the foregoing events shall constitute a Change of Control of the Company unless such event also constitutes a change
in ownership of the Company within the meaning of Treasury Regulation Section 1.409A- 3(i)(5)(v) or a change in ownership of a substantial
portion of the assets of the Company within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii).

 

	(f)	“Change
    of Control Date” means any date after the date hereof on which a Change of Control occurs.
	 	 
	(g)	“Code”
    means the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.
	 	 
	(h)	“Compensation
    Committee” means the compensation committee of the Board or such other committee of the Board that exercises the duties and
    responsibilities typically assigned to a compensation committee and if no such committee has been established, the Compensation Committee
    shall mean the full Board.

 

    	A-2

     

    

 

	(i)	“Confidentiality
    Agreement” means the Proprietary Information and Invention Agreement between the Company and the Executive, a copy of which
    is attached to this Agreement as Exhibit B, pursuant to which the Executive has agreed to abide by certain covenants (including covenants
    to maintain not to disclose confidential information, compete with the Company or solicit employees, consultants or independent contractors
    of the Company, main).
	 	 
	(j)	“Date
    of Termination” means the date specified in a written notice of termination delivered pursuant to Section 4 hereof, or the
    Executive’s last date as an active employee of the Company before a termination of employment due to his death or Non-Renewal.
	 	 
	(k)	“Disabled”
    or “Disability” means a mental or physical condition that renders the Executive substantially incapable of performing
    his duties and obligations under this Agreement, after taking into account provisions for reasonable accommodation, as determined
    by a medical doctor (such doctor to be mutually determined in good faith by the parties) for 180 day days (whether or not consecutive)
    within any twelve (12) consecutive month period.
	 	 
	(l)	“Equity
    Awards” means stock options, stock appreciation rights, restricted shares, restricted stock units, deferred stock, performance
    shares or performance units or any other stock-based awards granted by the Company to the Executive whether pursuant to the terms
    of an equity incentive plan or otherwise.
	 	 
	(m)	“Fiscal
    Year” means the fiscal year of the Company, which is the calendar year.
	 	 
	(n)	“Good
    Reason” means, unless the Executive has consented in writing thereto, the occurrence of any of the following:

 

	 	(i)	the
    assignment to the Executive of any duties materially inconsistent with the Executive’s position, including any change in status,
    title, authority, duties or responsibilities or any other action which results in a material diminution in such status, title, authority,
    duties or responsibilities;
	 	 	 
	 	(ii)	a
    material reduction in the Executive’s Base Salary without the Executive’s consent by the Company other than a reduction
    in Base Salary authorized by Executive;
	 	 	 
	 	(iii)	the
    relocation of the Executive’s principal office without his written consent to a location that increases the Executive’s
    one-way commute from his residence at the time such relocation becomes effective by more than 30 minutes;
	 	 	 
	 	(iv)	the
    failure of the Company to obtain the assumption in writing of the Company’s obligation to perform this Agreement by any successor
    to all or substantially all of the assets of the Company within 15 days after a Business Combination or a sale or other disposition
    of all or substantially all of the assets of the Company;
	 	 	 
	 	(v)	any
    material reduction in the Company’s willingness or obligation to indemnify the Executive against liability for actions (or
    inaction, as the case may be) in his capacity as an officer, director or employee of the Company; or
	 	 	 
	 	(vi)	a
    material breach of this Agreement by the Company;

 

	(o)	“Key
    Executive Incentive Plan” shall have the meaning set forth in Section 3(b) of the Employment Agreement.
	 	 
	(p)	“Release”
    shall have the meaning set forth in Section 6 of the Employment Agreement.
	 	 
	(q)	“Term
    of Employment” shall have the meaning set forth in Section 4 of the Employment Agreement.

 

    	A-3

     

    

 

EXHIBIT
B

 

PROPRIETARY
INFORMATION AND INVENTION AGREEMENT

 

    	B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]